Literature DB >> 854877

Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III.

A N Teien, M Lie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 854877     DOI： 10.1016/0049-3848(77)90150-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  27 in total

1.  Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux.

Authors:  Kakunoshin Yoshida; Hideo Wada; Masahiro Hasegawa; Hiroki Wakabayashi; Takeshi Matsumoto; Yuji Shimokariya; Katsura Noma; Norikazu Yamada; Atsumasa Uchida; Tsutomu Nobori; Akihiro Sudo
Journal:  Int J Hematol       Date:  2012-01-21       Impact factor: 2.490

2.  The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.

Authors:  A De Boer; J C Stiekema; M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

3.  Heparin resistance in acute coronary syndromes.

Authors:  Jonathan D Rich; John M Maraganore; Edward Young; Rosa-Maria Lidon; Burt Adelman; Paul Bourdon; Supoat Charenkavanich; Jack Hirsh; Pierre Theroux; Christopher P Cannon
Journal:  J Thromb Thrombolysis       Date:  2007-01-13       Impact factor: 2.300

4.  Dromedary glycosaminoglycans: molecular characterization of camel lung and liver heparan sulfate.

Authors:  Mohammad Warda; Robert J Linhardt
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2005-11-17       Impact factor: 2.231

5.  Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement.

Authors:  Kakunoshin Yoshida; Hideo Wada; Masahiro Hasegawa; Hiroki Wakabayashi; Honami Ando; Seika Oshima; Takeshi Matsumoto; Yuji Shimokariya; Katsura Noma; Norikazu Yamada; Atsumasa Uchida; Tsutomu Nobori; Akihiro Sudo
Journal:  Int J Hematol       Date:  2011-09-22       Impact factor: 2.490

6.  Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.

Authors:  J C Stiekema; H P Wijnand; T G Van Dinther; H C Moelker; J Dawes; A Vinchenzo; H Toeberich
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

7.  Twenty-four-hour venoarterial extracorporeal membrane oxygenation without systemic heparinization in dogs.

Authors:  K Miyasaka; M Takata; R Muto
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

8.  Development of a dosing strategy for enoxaparin in obese patients.

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

9.  Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

Authors:  D P Mikhailidis; V A Fonseca; M A Barradas; J Y Jeremy; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

10.  A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.

Authors:  J C Stiekema; J M Van Griensven; T G Van Dinther; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.